Search Results - technology+classifications+%3e+medical+%3e+therapeutics

71 Results Sort By:
Anti C. difficile Recurrence Vaccine Targeting Spore Colonization
Advantages Targets spore colonization, the root cause of CDI recurrence Broad coverage across diverse C. difficile strains Demonstrated protection in mice (reduced disease severity, toxins, and spore burden) Flexible delivery as injectable protein or oral L. lactis, enabling systemic + gut‑level immunity Summary Clostridioides difficile remains...
Published: 2/17/2026   |   Inventor(s): Xingmin Sun, Lubem Agbendeh, Soumyadeep Chakraborty
Keywords(s): Infectious Diseases, Vaccines
Category(s): Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Infectious Diseases, Technology Classifications > Medical > Therapeutics
ICA‑1S and ζ‑Stat: Selective aPKC Inhibitors for Anti‑Angiogenic Control Neuroblastoma
Advantages Upstream pathway control: Suppresses VEGF‑A by targeting aPKC, a master regulator of angiogenic signaling. Selective, small-molecule mechanism: offers lower immunogenicity and easier development than antibody-based therapies. Combination-therapy ready: upstream angiogenic pathway control enables synergy with existing treatments. Summary Neuroblastoma...
Published: 3/6/2026   |   Inventor(s): Sloan Breedy, Wishrawana Ratnayake, Mildred Acevedo-Duncan
Keywords(s): Cancer Treatment, Small Molecules
Category(s): Technology Classifications > Cancer, Technology Classifications > Chemistry, Technology Classifications > Medical > Oncology, Technology Classifications > Medical > Neuroscience, Technology Classifications > Medical > Therapeutics, Technology Classifications > Medical > Pharmaceuticals
Novel Therapy to Prevent Kidney Transplant Rejection
Advantages First-in-class mechanism: Only known PPP1R3G/PP1γ inhibitor—differentiated from all RIPK1/RIPK3 competitors Upstream targeting: Acts before RIPK1 activation for potentially improved selectivity Validated efficacy: Demonstrated reduction in necroptosis markers (p-RIP1, p-RIP3, p-MLKL) Large unmet need: No approved DGF prevention...
Published: 2/11/2026   |   Inventor(s): Lei Wang, Zhigao Wang, Jianfeng Cai
Keywords(s): Organ Transplantation, Renal / Kidney
Category(s): Technology Classifications > Medical > Biotechnology, Technology Classifications > Chemistry, Technology Classifications > Medical > Therapeutics
Acute Kidney Injury (AKI) Disrupts Cardiac Remodeling via Serpin A3N
Advantages Novel Mechanistic Insight: Identification of SerpinA3N-GZMB axis links AKI to cardiac fibrosis and dysfunction. New Therapeutic Target: targeting SerpinA3N-GZMB axis enables a novel treatment approach for maladaptive cardiac remodeling. Diagnostic and Drug Discovery Potential: SerpinA3N and GZMB could serve as biomarkers for diagnostics...
Published: 10/31/2025   |   Inventor(s): Gowda Pramod, Ruisheng Liu
Keywords(s):  
Category(s): Technology Classifications > Medical, Technology Classifications > Medical > Medical Diagnostics, Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical > Therapeutics
Exogenous Acetate Formulations for Treating Alcohol Use Disorder and Withdrawal
Advantages Mechanistic Innovation: stabilizes brain energy metabolism and modulates adenosine signaling mechanisms not targeted by current addiction therapies. Targeted Brain Delivery: formulations enable effective acetate transport across the blood-brain barrier, (BBB) Controlled and sustained release Versatile Administration Routes: compatible...
Published: 9/30/2025   |   Inventor(s): Dominic D'Agostino
Keywords(s): Neuroscience, Pharmaceuticals
Category(s): Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical > Therapeutics, Technology Classifications > Chemistry, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Neuroscience
Novel Heart Failure Therapy: Farnesyltransferase Inhibition Targets Protein Aggregation in Cardiomyocytes
Advantages First-in-Class Mechanism: Targets a novel pathway—protein farnesylation—for heart failure treatment. Broad Therapeutic Potential: Effective in both HFrEF and HFpEF, addressing a major unmet need. Tested in multiple preclinical models: Danon disease cardiomyopathy (genetic model); HFpEF (diet-induced and hypertensive models);...
Published: 11/7/2025   |   Inventor(s): Kunhua Song, Congwu Chi, Amanda Conniff
Keywords(s): Cardiovascular Diseases, Drug Repurpose, Medical Pharmaceuticals, Therapeutics
Category(s): Technology Classifications > Medical > Therapeutics, Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical > Biotechnology, Technology Classifications > Chemistry
A Novel Immunomodulatory Strategy for Treating Heart Failure in Aging Populations
Advantages Novel Mechanism of Action: Targets the Th17/IL17A signaling axis Validated Target: IL17A is already clinically validated in other inflammatory diseases (e.g., psoriasis, psoriatic arthritis), with FDA-approved therapies like secukinumab Strong Preclinical POC: transcriptomic, histological, and functional cardiac assessments showing reversal...
Published: 10/14/2025   |   Inventor(s): Wanling Xuan, Srinivas Tipparaju
Keywords(s): Cardiological Diseases Treatment, Cardiovascular Diseases, Drug Discovery
Category(s): zzCardiology, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Pharmaceuticals, Technology Classifications > Medical > Therapeutics
Spatiotemporal Drug Control in Autoimmune and Inflammatory Diseases: Photoswitchable JAK2 Inhibitors for Reversible Kinase Modulation
Advantages Precise spatiotemporal control and reversible modulation of kinase activity Reduced systemic toxicity and off-target effects Superior binding affinity and isomer selectivity than traditional Jak 2 inhibitor Summary Janus kinase 2 (JAK2), a key player in hematologic cancers and autoimmune diseases, is a particularly challenging target...
Published: 9/11/2025   |   Inventor(s): Shelby Kell, Chavdar Slavov
Keywords(s): Autoimmune Diseases, Inflammatory Diseases, Small Molecules, Therapeutics
Category(s): Technology Classifications > Medical > Biomedical Engineering, Technology Classifications > Medical > Therapeutics, Technology Classifications > Medical > Pharmaceuticals
CCR1 Antagonist for Hemorrhagic Shock Treatment
Advantages Significant reduction in fluid requirements without noticeable adverse events Clinically tested compound for multiple sclerosis, demonstrating favorable safety and tolerability profile Mitigation of inflammation and tissue edema Broad market potential in major surgeries, sepsis, burn care, and military medicine, where fluid management...
Published: 2/11/2026   |   Inventor(s): Matthias Majetschak, Xianlong Gao, Elizabeth Cook
Keywords(s): Critical Care / Trauma, Surgery
Category(s): Technology Classifications > Medical > Surgery, Technology Classifications > Medical > Therapeutics
Methionine Sulfoxide Reductase A (MsrA) Gene Therapy for Retinal Degeneration
Advantaages Targeted Protection Against Oxidative Stress Dual-Vector Delivery System (AAV and Lenti) Simple and scalable plasmid design for efficient production Suitable for major ophthalmology indications: Age-related macular degeneration (AMD), Retinitis pigmentosa, other oxidative stress-related retinal degenerations Summary Oxidative stress...
Published: 10/14/2025   |   Inventor(s): Manas Biswal
Keywords(s): Ophthalmology, Pharmaceuticals
Category(s): Technology Classifications, Technology Classifications > Medical > Biomedical Engineering, Technology Classifications > Medical > Biotechnology, Technology Classifications > Medical > Cell & Tissue Engineering, Technology Classifications > Medical > Therapeutics, Technology Classifications > Medical > Pharmaceuticals
1 2 3 4 5 6 7 8